Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com
Rgenix-lab-new-york

Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System

Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019

 

Masoud Tavazoie

Masoud Tavazoie

Masoud Tavazoie, Rgenix CEO and Co-Founder speaks at Immuno-Oncology 360°

In its 5th year, the IO360 conference brings together diverse stakeholders of drug development in immuno-oncology (IO). The multi-disciplinary approach of IO has been key to its tremendous advances in the treatment of cancer, but also created unforeseen challenges. While the number and types of agents in development has exploded, and with it the number of clinical trials and combination studies, the multitude of recent failures suggest that the understanding of the field is still in its infancy. IO360 sheds light on advances and challenges of IO, both from a scientific, translational, clinical, regulatory, financial and organizational viewpoint.

Dr. Tavazoie’s talk will highlight strategies to support the translation of preclinical data into the clinic specifically for modalities targeting the innate immune system. These strategies aim to improve our understanding of disease mechanics and a better matching of therapy and patient, with the goal of achieving better patient outcomes more effectively.